Loading...
NPI 1366183857 · Bloomingdale, IL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Advanced Clinical Laboratory Inc is a clinical medical laboratory provider located in Bloomingdale, Illinois. This profile covers 5 Medicare and 5 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Advanced Clinical Laboratory Inc |
| Address | 1 Tiffany Pt Ste G15 |
| City | Bloomingdale |
| State | IL |
| ZIP | 60108 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | April 6, 2022 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $5.2M |
| Medicaid | $867.2K |
Business profile: The provider is classified as a Clinical Medical Laboratory and its paid-service mix is tightly concentrated in SARS‑CoV‑2 testing and associated specimen services (codes K1034, U0003, U0005, G2023 and 87811). That pattern indicates the operation is primarily processing COVID‑19 diagnostic tests and specimen collection rather than a broad portfolio of general clinical laboratory assays.
Medicare revenue concentration: This provider’s Medicare revenue is heavily concentrated in a very small set of procedures — the precomputed top 3 Medicare codes account for 98.6% of total Medicare revenue, with K1034 alone reporting $4.8M revenue (93.5% of this provider's total Medicare revenue). Such concentration means Medicare performance and reimbursement policy changes for these specific codes would drive most of the provider’s Medicare financial outcomes.
Medicaid revenue concentration: Medicaid billing is also concentrated, with the precomputed top 3 Medicaid codes accounting for 86.1% of total Medicaid revenue. The largest Medicaid contributors are U0003 ($389.2K, 44.9%), 87811 ($229.9K, 26.5%), and U0005 ($127.2K, 14.7%), showing a similar COVID‑testing–centric revenue mix on the state payer side.
Payer mix and scale: The provider reports total Medicare revenue of $5.2M versus total Medicaid revenue of $867.2K, indicating Medicare is the substantially larger revenue source. While the practice bills both payers, Medicare dominates the revenue base in absolute scale.
Medicare competitive standing and outlier status: For Medicare, K1034 is an extreme outlier nationally (ranks #94 of 30143 providers nationally; 100th percentile, described as "extreme outlier, far above typical national volume for this code"), making this provider unusually large for that specific service. Other Medicare codes (U0003, U0005, G2023) have ranking percentiles characterized as typical or unremarkable for their peer sets despite contributing smaller shares of Medicare revenue.
Medicaid competitive standing in-state: Within Illinois Medicaid claims, the provider is a significant in-state participant for certain tests — 87811 ranks #17 of 548 providers in-state (97th percentile), indicating comparatively high in-state volume for that assay. U0003 and U0005 sit at higher-but-typical in-state percentiles (U0003: #45 of 350, 87th percentile; U0005: #40 of 210, 81th percentile), making the provider a solid but not dominant statewide player for those molecular testing codes.
Tenure and operational implication: The provider’s NPI was enumerated on 2022-04-06 (~4 years ago), and within a relatively short tenure it has built a high-volume COVID‑testing business line. The combination of recent enumeration and concentrated code mix suggests a rapid operational focus on pandemic-era diagnostic testing services rather than a long-standing, diversified clinical lab footprint.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 403,580 | $10 | $4.8M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 2,720 | $70 | $201.4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 2,720 | $30 | $67.9K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2,710 | $20 | $62.4K |
| 87811 | The lab analyst performs the technical lab test to analyze for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (Coronavirus disease [COVID–19]) in a specimen by… | 190 | $40 | $7.6K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 5 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 7,490 | $50 | $389.2K |
| 87811 | The lab analyst performs the technical lab test to analyze for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (Coronavirus disease [COVID–19]) in a specimen by… | 7,180 | $30 | $229.9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 7,490 | $20 | $127.2K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 7,490 | $20 | $119.8K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 370 | $1 | $1.1K |
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
5 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 45 | 350 | 400 | $70 | $514.7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 40 | 210 | 680 | $20 | $206.4K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 33 | 400 | 550 | $20 | $90.8K |
| 87811 | The lab analyst performs the technical lab test to analyze for the presence of severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) (Coronavirus disease [COVID–19]) in a specimen by… | 17 | 550 | 240 | $40 | $42.4K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 37 | 60 | 660 | $1 | $3.2K |
Other providers in the same ZIP code as Advanced Clinical Laboratory Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Access Community Health Network | IL | Federally Qualified Health Center (FQHC) | $0 | $9.3M |
| Aqeel Khan | IL | Psychiatry Physician | $2.2M | $3.5M |
| Bloomingdale Fire Protection District 1 | IL | Land Ambulance | $364.8K | $5.1M |
| Sang Han | IL | Pediatrics Physician | $0 | $3.1M |
| Courtney Burland | IL | Physician Assistant | $1.4M | $0 |
| Momin Muzaffar | IL | Diagnostic Radiology Physician | $307.9K | $36.2K |
| Sana Atcha | IL | Family Nurse Practitioner | $266.9K | $5.4K |
| Mandeep Kohli | IL | Internal Medicine Physician | $160.3K | $66.1K |
| Michael Vosicky | IL | Family Medicine Physician | $158.7K | $0 |
| Nicole Tymann | IL | Nurse Practitioner | $45.7K | $81.2K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.